Barclays upgraded Celldex (CLDX) to Overweight from Underweight with a price target of $45, up from $24. The firm has conviction in a successful Phase 3 readout in chronic spontaneous urticaria. Barclays says it “can’t ignore” the faster than expected enrollment in the Phase 3 EMBARQ trial six months ahead of schedule and the Q4 readout of the study. At a minimum this speaks to the demand and enthusiasm for barzolvolimab, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex Announces Major Underwritten Public Equity Offering
- Celldex 10.345M share Spot Secondary priced at $29.00
- Closing Bell Movers: Globalstar spikes on acquisition report
- Celldex announces common stock offering, no amount given
- Celldex data shows improvements across six DLQI Domains in barzolvolimab trials